Vinpocetine
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Vinpocetine: From Cerebrovascular Disorders to Coronary Artery Disease
One-Sentence Summary
Vinpocetine is internationally used for cerebrovascular disorders and age-related memory impairment, acting as a phosphodiesterase 1 (PDE1) inhibitor. The TxGNN model predicts it may be effective for Coronary Artery Disease, but this direction is currently supported only by 3 pieces of literature (mostly older observational/animal studies) and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not officially registered in India; internationally described (DrugBank pharmacology data) for cerebrovascular disorders and age-related memory impairment |
| Predicted New Indication | Coronary Artery Disease |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No structured original_moa record is currently available for Vinpocetine. However, pharmacology target data confirms it acts as an inhibitor of phosphodiesterase 1A and 1C (PDE1A/PDE1C). By blocking PDE1-mediated hydrolysis of cyclic nucleotides, Vinpocetine raises intracellular cAMP/cGMP levels, producing vasodilation, inhibition of platelet aggregation, and improved microcirculation — this is the pharmacological basis of its established international use in cerebrovascular disorders and age-related memory impairment.
The proposed link to coronary artery disease is a mechanistic extrapolation: cerebral and coronary circulation share vasodilatory and platelet-related pathways, so a PDE1-driven increase in blood flow could theoretically extend from the brain to the heart. However, the existing literature evidence is concentrated almost entirely on the cerebrovascular system, not on coronary atherosclerosis pathology (e.g., plaque stability, lipid metabolism). The connection to CAD is therefore indirect inference rather than disease-specific mechanistic evidence.
Some older Soviet/Hungarian observational studies (e.g., hemodynamic and adenosine metabolism effects in atherosclerosis patients) hint at a broader vascular benefit, but these predate modern trial standards and were not designed with CAD-specific endpoints. Overall, the biological plausibility is reasonable but the direct disease-specific evidence remains weak.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 17631470 | 2007 | Review | Orvosi hetilap | Reviews vinpocetine’s role in cerebrovascular disease; notes coronary artery disease as the second leading cause of death after cerebrovascular disease, and highlights the importance of restoring cerebral blood flow in hypoperfused patients |
| 3188457 | 1988 | Cohort | Vrachebnoe delo | Small clinical hemodynamic study of kavinton (vinpocetine) on hemodynamics and adenosine metabolism in atherosclerosis patients |
| 15377497 | 2005 | Experimental (animal/vascular) | Am J Physiol Lung Cell Mol Physiol | PDE inhibitors potentiate prostacyclin analog effects on hypoxic pulmonary vascular remodeling; supports PDE-mediated vasoactive mechanism, but in pulmonary rather than coronary vasculature |
India Market Information
Vinpocetine is not currently marketed in India; no CDSCO product registrations are on file, so no authorization/license table is available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: key warnings and contraindications data are currently unavailable. Pharmacology database records show Vinpocetine binds PDE1A and PDE1C as its known targets, but no formal drug-drug interaction data has been compiled.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for the coronary artery disease indication is limited to Evidence Level L4 (mechanistic/preclinical and older, non-CAD-specific observational studies), with no registered clinical trials evaluating this indication directly. Combined with the drug not being marketed in India and a Blocking data gap on package-insert warnings/contraindications (required for initial safety screening), the evidence base is not yet sufficient to advance beyond a research question.
To proceed, the following is needed:
- India (CDSCO)-equivalent package insert warnings and contraindications (currently a Blocking data gap)
- Structured mechanism-of-action data from DrugBank (currently a High-severity data gap)
- Dedicated clinical trials or controlled studies evaluating Vinpocetine specifically in coronary artery disease/myocardial ischemia populations
- Confirmation of India market/regulatory pathway if development is pursued
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.